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Abstract 
Hepatitis C virus (HCV) heterogeneity accounts for the failure of effective vaccine devel-
opment and the lack of successful anti-viral therapy in some patients. Little is known about 
the immune response to HCV peptides and the region or race specific genotypes in China. 
The objective of this study was to characterize HCV antibody immune response to HCV 
peptides and HCV genotypes in different regions and races of China. A total of 363 serum 
samples were collected from HCV carriers in 6 regions in China. The immune response to 
HCV peptides was evaluated by ELISA. HCV genotypes were examined using nested 
RT-PCR. We found that the anti-HCV antibody neutralization rates were significantly dif-
ferent among the serum samples from different areas or from different races in the same 
area. For samples from Tibet and Sinkiang, the rates of neutralization by HCV peptides were 
only 3.2% and 30.8%, respectively. The genotypes of samples from Tibet and Sinkiang were 
apparently heterogeneic and included type I, II, III and multiple types (I/II/III, I/II, I/III, II/III). 
One specific sample with multiple-genotype (I/II/III) HCV infection was found to consist of 
type I, II, III, II/III and an unclassified genotype. These studies indicate that the anti-HCV an-
tibody immune response to HCV peptides varied across regions and among races. The dis-
tribution of HCV genotypes among Tibetans in Tibet and Uighurs in Sinkiang was different 
from that in the inner areas of China. In addition, a “master” genotype, type II, was found to 
exist in HCV infection with multiple HCV genotypes. 
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Introduction 
The incidence of Hepatitis C virus (HCV) infec-
tion has been steadily increasing in the last few dec-
ades in China and is expected to intensify in the 
coming years worldwide [1]. Peptide-based vaccines Int. J. Biol. Sci. 2009, 5 
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have been generated and tested in pre-clinical and 
clinical trials [2]. However, the development of effec-
tive peptide-based vaccines has been significantly 
hampered by the high genetic variability of HCV. 
Anti-viral humoral immune response plays a 
fundamental role during HCV infection. Viral clear-
ance is associated with the production of 
anti-envelope antibodies, and high serum levels of 
anti-viral envelope antibodies can prevent HCV in-
fection in chimpanzees [3]. Nevertheless, the correla-
tions between antibody production and its potential 
neutralizing immune response are still largely un-
known.  
HCV belongs to the hepacivirus genus in the 
Flaviviridae family [4]. There are 6 different geno-
types of HCV and more than 70 sub-types based on 
the nucleic acid sequences [5]. HCV is therefore char-
acterized by high levels of genetic heterogeneity, 
which accounts for the difficulties in vaccine devel-
opment and for the lack of therapeutic efficacies. In 
China, the prevalence of HCV genotypes I and II has 
been previously reported [6]. However, little is known 
about the immune response to HCV peptides, and the 
region-specific distribution of HCV genotypes in 
China has not been fully evaluated.  
In this report, we conducted serological and 
molecular studies on a large cohort of HCV carriers in 
6 regions of China to determine the HCV antibody 
immune responses to HCV peptides and the distribu-
tion model of HCV genotypes in different areas and 
races of China. 
Materials and Methods 
Study population 
Human HCV-positive serum samples from 363 
HCV-infected patients were collected from hospitals 
in different areas of China: 35 from Shanghai, 20 from 
Shaanxi, 19 from Tianjin, 62 Tibetans, 23 Hans from 
Tibet, 146 Uighurs, 42 Hans from Sinkiang, and 16 
from Hebei (Table 1). The selection of the study 
population was based on the following criteria: pres-
e n c e  o f  H C V  R N A  i n  p l a s m a  c o n f i r m e d  b y  n e s t e d  
reverse transcription polymerase chain reaction 
(nRT-PCR); absence of other concomitant liver dis-
eases; negative HIV test; no prior interferon and/or 
ribavirine treatment, and neither habitual alcohol nor 
active intravenous drug users. Control serum samples 
(n=3) were obtained from subjects who were negative 
for Hepatitis A, B, C, CMV (cytomegalovirus) and 
HIV. The peptides CP1, CP2 and NS4 used in this 
study were prepared in our laboratory:  
CP1 (5~46): PKPQRKTKRNTNRRPQDVKFPGG 
GPIVGGVYLLPRRGPRLGV 
CP2(39~80): RRGPRLGVRATRKTAERSQPRGR 
RQPIQKARRPEGRTWAQPGY 
NS4(1694~1735): IIPDREVYREFDEMEECSQHL 
PYIEQGMMLAEQFKQKALGLL.  
Table 1: Characters of 363 HCV-infected patients in different areas of China 
 Sample  Number 
Province Hebei  Shanghai  Shannxi  Tianjin  Tibet 
(Tibetans) 
Tibet 
(Hans) 
Sinkiang 
(Uighurs) 
Sinkiang 
(Hans) 
Total  number  16  35 20 19 62 23 146  42 
G e n d e r :            
Male  9  14 11 12 30 12 83 22 
Female  7  21 9  7  32 11 63 20 
Age: 
(years old) 
         
10～20  1  3 0 1 2 1 16  3 
21～30  4  10  6 6 13  5 39  21 
31～40  5  7 7 6 24  7 52  15 
41～50  2  5 4 5 11  4 31  2 
51～60  4  6 3 1 6 5 7 1 
61～70  0  4 0 0 6 3 1 0 
 
Anti-HCV ELISA 
All 363 serum samples were screened for 
anti-HCV antibodies using ELISA (Bio-Rad, 
Marne-La-Coquette, France). The results of the assay 
were expressed quantitatively as the ratio of the op-
tical density of the test sample to the calculated cut-off 
absorbance as recommended by the manufacturer. 
Serum samples with OD values ≥ 0.30 were consid-
ered to be positive, while those with OD values < 0.30 
were considered negative. Positive and indeterminate 
serum samples were re-tested with another ELISA 
assay, Innotest HCV Ab IV (Innogenetics NV HCV, 
Gand, Belgium). Samples were confirmed as 
anti-HCV antibody positive when they were tested 
positive using both ELISA sets.  Int. J. Biol. Sci. 2009, 5 
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Neutralization of anti-HCV antibodies 
For the neutralization experiments using ELISA, 
10µl complex peptides (CP1, CP2, and NS4, 
200µg/ml) were added to 90µl serum samples (1:10 
dilution in PBS) and incubated 1h at 37°C. Ten micro-
liters of each serum sample and the same sample in-
cubated with the peptides were tested with the HCV 
ELISA as described previously [7-8]. The cutoff for the 
assay was established for each test from internal con-
trols. Previously tested anti-HCV negative blood 
samples and the diluted buffers served as negative 
controls. An OD value reduced by >50% was used to 
indicate a positive neutralization. Anti-HCV neu-
tralization ratios in different regions or races = 
(Anti-HCV neutralization positive sample num-
bers/Anti-HCV positive sample numbers)×100%. 
HCV RNA detection 
HCV RNA preparation and cDNA synthesis 
were performed as described previously[9]. The ex-
tracted RNA was used as a template and was ampli-
fied by nested RT-PCR with primers specific for the 
5'UTR (5' non-coding region) of HCV[10-11]. PCR 
products were re-amplified using the same cycling 
program. Negative controls lacking template were 
included for each pair of primers. If a control was 
found positive, all of the PCR products in that set 
w e r e  c o n s i d e r e d  t o  b e  c o n t a m i n a t e d  a n d  w e r e  d i s -
carded. Amplified cDNA was electrophoresed by 
2.0% agarose gel and stained with ethidium bromide. 
Genotyping of HCV 
HCV genotypes were determined by 
ampliﬁcation of the core region with geno-
type-speciﬁc primers that distinguished between 
genotypes I, II, III and IV [12-13]. Part of the HCV core 
gene (272 bp) was amplified from HCV cDNA with 
universal primers. A portion of the product was then 
amplified by PCR with universal sense primers and a 
mixture of five antisense primers deduced from HCV 
core (HCV-C) gene sequences specific for genotypes I, 
II, III and IV [12, 14]. The four genotypes were dis-
tinguished from one another by the size of the PCR 
products: 123 bp for genotype I; 211 bp for II; 240 bp 
for III and 188 bp for IV. 
Cloning, sequencing and analysis of partial 
HCV-C gene from a multi-genotype (I/II/III) se-
rum sample of a Uighur 
The PCR products from a serum sample of a 
Uighur with multi-genotype (I/II/III) HCV infection 
were cloned into T-vector which was then transferred 
into E.coli XL1-Blue and cultured in LB plate at 37°C 
overnight. Recombinant clones were selected ran-
domly and positive clones were detected and geno-
typed by PCR as described above. Partial HCV-C 
genes from the positive clones were amplified by 
nest-PCR with external primers 
5'-ATGAGCACGAACATTCCTAAAACC-3' and 
5'-AGCGGAAGCTGGGAGTGGT-3' and internal 
primers: 5' -CACTCTCGAGCACCCTATCAGGCA 
GT-3' and 5'-TTCACGCAGAAAGCGTCTAG-3'. 
Positive and negative controls were included at the 
extraction step and in both rounds of amplification. 
PCR products were sequenced using the dide-
oxy-mediated chain-termination method with a 373A 
Automatic DNA Sequence Analysis Machine (Ap-
plied Biosystems, Weiterstadt, Germany). Individual 
sequences were analyzed with MegAlign software 
(DNAStar Inc., Madison, WI). 
Statistics 
Data are expressed as means ± SD. Statistical 
analysis was conducted using StatView. Significant 
differences between groups were determined by 
ANOVA, and p<0.05 was considered significant. In 
order to detect the differences among categorical 
variables of neutralization rate (%), chi-square (χ2) test 
was applied. In order to detect differences among 
categorical variables of neutralization OD±SD, t test 
(t) was applied. 
Results 
Anti-HCV neutralization 
The results in Table 2 show that anti-HCV neu-
tralization rate was significantly different among the 
human serum samples collected from different areas 
of China. The neutralization rate in samples collected 
in Hebei was the highest (87.5%). The rates in Shang-
hai, Shaanxi, Tianjin were intermediate, and the rates 
in samples from Tibet and Sinkiang were low. Only 2 
of the 62 (3.2%) serum samples from Tibet were neu-
tralized by the HCV complex antigens.  
The data in Table 2 also show. that 
pre-neutralization, the OD value of samples from 
Tianjin was the highest (1.54±0.64), while that of 
samples from Tibet was the lowest (0.66±0.26). 
Post-neutralization, the average OD values of samples 
from Shanghai, Shaanxi, Tianjin and Hebei apprecia-
bly declined (by 50% or nearly 50%), indicating that 
those samples were significantly neutralized. The OD 
value of samples from Sinkiang (Uighurs), however, 
declined slightly (by about 35%), and the OD value of 
samples from Tibet (Tibetans) barely declined (3.3%). 
Table 3 shows that the neutralization rate and Int. J. Biol. Sci. 2009, 5 
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average OD values pre- and post-neutralization were 
significantly different among the serum samples col-
lected from different races in Tibet and Sinkiang. The 
neutralization rates of Hans in the same area were 
higher than that of other races, and the OD values of 
Hans declined more significantly than that of the 
other races in the same area.  
HCV genotypes 
The results in Fig.1 show that the HCV genotype 
among Tibetans was mainly type II (33/69, 47.8%), 
followed by type II/III (20/69, 29.1%). Other geno-
types were rare. The HCV genotypes among Uighurs 
in Sinkiang, however, were mainly type I/II (27/81, 
33.3%), followed by type I/II/III (19/81, 23.5%), and 
type II (14/81, 17.3%). 
The results in Table 4 indicate that most type I 
samples (7/11, >60%) were anti-HCV negative. The 
type I anti-HCV positive samples could not been 
neutralized by the complex antigens used in this 
study. Furthermore, the average OD values for type I 
was lower than others. Most type II samples (42/47, 
>80%) were anti-HCV positive and some of these 
samples could be neutralized. The type II samples had 
high OD values that clearly declined 
post-neutralization. In addition, the neutralization 
rate was different for the same genotype in samples 
collected from different areas. For example, the neu-
tralization rate of type II from Tibet (Table 5: 6.9%) 
w a s  m u c h  l o w e r  t h a n  t h a t  f r o m  S i n k i a n g  ( T a b l e  6 :  
61.5%).
Table 2: Anti-HCV antibody neutralization in serum samples collected from different areas of China and the average OD 
values pre- and post-neutralization 
Source of sam-
ples 
Number of 
anti-HCV positive 
samples 
Number of samples 
neutralized with HCV 
peptides 
Neutralization rate(%)  Pre- neutralization 
OD±SD 
Post- neutralization 
OD±SD 
Shanghai 35  23  65.7  0.83±0.63  0.36±0.34 
Shaanxi 20  10  50.0  0.77±0.57  0.33±0.26 
Tianjin 19  12  63.2  1.54±0.64  0.79±0.72 
Tibet (Tibetans)  62  2  3.2  0.66±0.26  0.64±0.28 
Sinkiang 
(Uighurs) 
146 45  30.8  0.98±0.54  0.64±0.36 
Hebei 16  14  87.5  0.84±0.74  0.18±0.16 
χ2=70.57, P<0.001; t=2.978, P<0.05 
(χ2 stands for chi-square test; t stands for t test) 
 
Table 3: Anti-HCV antibody neutralization in serum samples collected from different races in Tibet and Sinkiang 
Source of serum 
Area Race 
Number of 
anti-HCV posi-
tive samples 
Number of samples 
neutralized with 
HCV peptides 
Neutralization rate(%)  Pre - neutraliza-
tion OD±SD 
Post- neutralization 
OD±SD 
Tibet Tibetans  62  2  3.2* 0.66±0.26  0.64±0.28Δ 
Tibet Hans  23  8  34.7* 0.82±0.34  0.61±0.32Δ 
Sinkiang Uighurs 146  45  30.8** 0.98±0.54  0.64±0.36ΔΔ 
Sinkiang Hans  42  25  59.5** 0.87±0.41  0.48±0.38ΔΔ 
*χ2=13.20, P<0.001; ** χ2=11.50, P<0.001; Δt=1.41, P>0.05; ΔΔt=3.75, P<0.05 
(χ2 stands for chi-square test; t stands for t test) 
 
Table 4: Relations of genotypes, average OD values and neutralization rates  
Genotype 
(number) 
Anti- 
HCV  
(-) 
Anti- 
HCV  
(+) 
Number of samples 
neutralized with 
HCV peptides 
Neutralization 
rate(%) 
Pre- neutralization 
OD±SD 
Post- neutralization 
OD±SD 
I (11)  7  4  0  0  0.38±0.32  0.37±0.28 
II (47)  5  42  10  23.8  0.94±0.40  0.67±0.42 
III (7)  1  6  1  16.7  0.69±0.38  0.51±0.43 
I/II/III (21)  4  17  9  52.9 0.67±0.52  0.52±0.48 
I/II (31)  7  24  11  45.8  0.74±0.44  0.61±0.34 
I/III (4)  1  3  1  33.3  0.74±0.27  0.60±0.32 
II/III (29)  6  23  5  21.7 0.89±0.37  0.62±0.36 
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Table 5: Relations of genotypes, average OD values and neutralization rates in Tibet 
Genotype (num-
ber) 
Anti- 
HCV  
(-) 
Anti- 
HCV  
(+) 
Number of samples 
neutralized with 
HCV peptides 
Neutralization 
rate(%) 
Pre- neutralization 
OD±SD 
Post- neutralization 
OD±SD 
I(3) 2  1  0  0  0.32  0.31 
II(33) 4  29  2  6.9  0.68±0.25  0.66±0.27 
III(4) 1  3 0  0  0.44±0.34 0.41±0.35 
I/II/III(2) 1  1  0  0  0.36  0.31 
I/II(4) 1 3  0  0  0.57±0.32  0.54±0.26 
I/III(3) 1  2  0  0  0.62±0.27  0.57±0.32 
II/III(20) 5  15  0  0  0.65±0.28  0.60±0.27 
Table 6: Relations of genotypes, average OD values and neutralization rates in Sinkiang 
Genotype (num-
ber) 
Anti- 
HCV (-) 
Anti- 
HCV  
(+) 
Number of samples 
neutralized with 
HCV peptides 
Neutralization 
rate(%) 
Pre- neutralization 
OD±SD 
Post- neutralization 
OD±SD 
I(8) 5  3  0  0  0.43±0.32  0.42±0.28 
II(14) 1  13  8  61.5  1.20±0.54  0.68±0.56 
III(3) 0  3 1  33.3  0.94±0.41  0.60±0.51 
I/II/III(19) 3  16  9  56.2 0.98±0.52  0.72±0.48 
I/II(27) 6  21  11  52.4  0.92±0.55  0.68±0.42 
I/III(1) 0  1  1  100.0 0.85  0.62 
II/III(9) 1  8  5  62.5  1.12±0.46  0.64±0.44 
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Figure 1. The HCV genotype of serum samples collected in Tibet and Sinkiang. The total number of sera collected in Tibet 
and in Sinkiang was 69 and 81 respectively. The results show that the HCV genotype among Tibetans was mainly type II 
(33/69, 47.8%), followed by type II/III (20/69, 29.1%). Other genotypes were rare. The HCV genotypes among Uighurs in 
Sinkiang, however, were mainly type I/II (27/81, 33.3%), followed by type I/II/III (19/81, 23.5%), and type II (14/81, 17.3%). 
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 Cloning, sequencing and analysis of a partial 
HCV-C gene from a multi-genotype (I/II/III) se-
rum sample of a Uighur 
Partial HCV-C gene from a multi-genotype 
(I/II/III) infected Uighur was cloned and the recom-
binant clones were selected randomly. One hundred 
and forty two positive clones were confirmed and 
genotyped. They consisted of 1 type I (0.70%), 85 type 
II (59.86%), 40 type III (28.17%), 14 type II/III (9.86%) 
and 2 unclassified genotypes (1.41%). Genotype II was 
the most common. The sequences of the five clones 
that represented each of the five genotypes showed 
that the method used in this study for HCV genotyp-
ing could obviously differentiate among genotypes I, 
II and III. The genotypes II and III were not clearly 
distinguishable because the sequence of the type II/III 
clones was more closely related to genotype II. The 
sequence of the unclassified HCV genotype clone was 
also similar to that of type II. The DNA and amino 
acid sequences (data not shown) of these 5 clones 
were different from each other, and the DNA se-
quence homology of these 5 clones were 85%~98%. 
 
Discussion 
Genotyping of HCV strains is important in epi-
demiological studies and clinical practice. In particu-
lar, examination of sequence diversity can help un-
derstand the different patterns of serological reactiv-
ity, virulence and response to treatment [5, 15]. While 
it has been known that effective T cell response is es-
sential in HCV infection [16-17], neutralizing anti-
bodies also play a critical role [18]. It was observed 
that immunoglobulin prophylaxis could protect 
against HCV infection [19-20]. Studies of acutely in-
fected cohorts also show that rapid induction of neu-
tralizing antibodies may provide protection [21-22]. 
Moreover, antibodies present during the acute phase 
of infection can neutralize an infectious dose of HCV 
administered to chimpanzees [23]. Results from a 
different study also suggested that chronically in-
fected patients develop low levels of or no neutraliza-
tion antibodies [24-26]. Therefore, sequence differ-
ences among viruses may determine their suscepti-
bility to neutralizations by antibodies. Investigating 
the nature of antigen-antibody interaction in HCV 
infections may lead to a better understanding of the 
lack or poor neutralizing efficacy of antibodies, and 
help developing novel therapeutic strategies using 
specific anti-HCV immunoglobulin.   
In this report, we demonstrated that the 
anti-HCV neutralization rate and average OD values 
of pre- and post-neutralization were significantly dif-
ferent among human serum samples from different 
areas of China or from different races in the same 
area. In particular, in serum samples from Tibet and 
Sinkiang, only 3.2% and 30.8% of anti-HCV positive 
serum samples were neutralized by the HCV peptides 
(Table 2). These data suggest that the immune re-
sponse to HCV peptides derived from a single HCV 
genotype varies depending on region and race. One 
reason for this may be that the titer of anti-HCV an-
tibody in serum is different in different regions or 
among different races. Alternatively, the HCV geno-
types may be different. 
The response to therapy is dependent on several 
factors, e.g. viral genotypes and patient characteristics 
[1]. Therefore, it is important to track different geno-
types of HCV virus in clinic [27]. In this study, we 
showed that the distribution of HCV genotypes 
among Tibetans and Uighurs was different from that 
in inner areas of China. In HCV RNA positive samples 
from Tibetans and Uighurs, there were 3 types, type I, 
type II, type III and multiple types (Fig.1). In most 
provinces of inner China, the prevalence of HCV 
genotypes I and II has been previously reported [6]. 
Genotype I viral strain is the most prevalent and most 
difficult to treat in Europe and North America and 
represents the greatest unmet treatment need. Geno-
types II and III appear to be more prevalent in the Far 
East. Among the other genotypes, genotype IV was 
first found predominantly in the Middle East [28] and 
then in central Africa [6, 29-31], while genotypes V 
and VI are predominant in South Africa and 
South-East Asia, respectively [27]. This HCV hetero-
geneity could bring about a series of puzzles in the 
diagnosis of HCV infection and in the development of 
HCV vaccines. 
In this study, multiple-genotype (I/II/III) HCV 
infection was detected by nest-PCR (Fig.1, Table 4, 5, 
6). In particular, we found that a “master” genotype, 
type II (59.86%), exists in multiple infection with dif-
ferent HCV genotypes, and this is probably re-
gion-specific or race-specific. 
The infection of different genotypes with differ-
ent polypeptide antigens for anti-HCV positive pa-
tients in different regions of China is still unknown. 
Vicente Sentandreu et al. suggested that recombina-
tion should be considered as a potentially relevant 
mechanism of genetic variation in HCV [32]. Further 
studies focused on recombination among different 
HCV genotypes/subtypes may lead to more effective 
prevention and treatment for HCV infection.  Int. J. Biol. Sci. 2009, 5 
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